Tackling the Kokoda Trail for melanoma
6 April 2018
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark “Bod” Boddison.
Fraser’s trek fell in the middle of Melanoma Institute Australia’s major fundraising and awareness campaign Melanoma March which spans across 22 locations around the country, supporting, remembering and fundraising for past and present melanoma patients.
Out of sight, does not mean out of mind for Fraser and Bod. Friends for nearly 40 years, the pair remained very close after Fraser relocated to Australia from Scotland 19 years ago. “We kept in regular contact despite being on the other side of the world. He visited me in Oz on a number of occasions and I took my family to Scotland and we spent our 40th Birthday’s together”.
Bod was diagnosed with melanoma 11 years ago but was given the all clear. Six years later, due to the viciousness of melanoma, Bod had tumours in his brain, abdomen and other parts of his body. But Bod did not lose his sense of humour or positive attitude. Fraser flew to Scotland to spend some time with his lifelong friend. “Those two weeks were priceless for us”, Fraser said.
Devastatingly, Bod lost his battle on March 11th last year. Fraser took on Kokoda just over one year since Bod passed away. Fraser is hoping to fundraise and raise awareness about melanoma. Even though Scotland doesn’t cop the brunt of extreme UV rays like Australia, melanoma doesn’t discriminate.
Bod left behind his wife Ailsa and daughter Zoe who I keep in regular contact with and they are coping as well as can be expected. I also speak regularly to Bod's parents whom I have known since I was a little schoolboy & I find it very difficult speaking to them as I can hear just how terribly sad they are without Mark.
With three young children who spend a lot of time playing outside, Fraser is patently aware of the dangers of too much sun. “I was shocked to read the statistics regarding young Aussies and melanoma so that fortified my decision to raise funds”, Fraser said.
Fraser braved harsh terrain and difficult trekking conditions including extreme humidity and wet conditions. Fraser took on an incredible challenge for Melanoma Institute Australia and you can help him take it one step further by donating to his cause here.
Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.
Melanoma March is thrilled to introduce Ricky as our official Principal Partner for 2019!
World record holder, Olympian and Australian swimming champion Cate Campbell has been announced as National Ambassador for Melanoma Institute Australia (MIA) and its national awareness and fundraising campaign, Melanoma March.
MIA's expertise was essential to a recent Nature publication spearheaded by Perth’s Telethon Kids Institute and The University of Melbourne.
MIA is delighted to be hosting the MD Anderson pathologist on his first ever trip to Australia.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for dabrafenib and trametinib.
Three students from Arden Anglican School in Epping have won Melanoma Institute Australia’s (MIA) inaugural SunSafe Student Ambassador Award.
Mark Whittaker’s ‘Here comes the sun; Defending our summer rays’ (GW 24 Nov) clouds the sun-safe message – which could have disastrous consequences.
Professor Georgina Long is among only 12 researchers from the University of Sydney to be named in the 2018 Highly Cited Researchers List.
‘Wearing sunscreen should be as automatic as wearing a seatbelt. Both are potential life savers.’
The Poche Centre to host 3D total-body imaging system as part of world-first initiative to save lives from melanoma
A prestigious $10 million Australian Cancer Research Foundation grant has been awarded to ACEMID, an initiative that aims to use 3D total-body imaging and a remote medicine network to improve the detection and diagnosis of early-stage melanoma.
Professor Georgina Long and Professor Richard Scolyer have been recognised as world leaders in melanoma research for their ground-breaking work that has changed the diagnosis and treatment landscape of melanoma world-wide, and tripled the life-expectancy of advanced melanoma patients.
Leading researchers from Melanoma Institute Australia have taken out the top accolades at the NSW Premier’s Awards for Outstanding Cancer Research.
An impressive contingent of female delegates from Melanoma Institute Australia have presented findings across the whole spectrum of melanoma research at the Society for Melanoma Research 2018 Congress in Manchester, England.
Over 800 researchers and clinicians from around the world were welcomed to Manchester for the 15th International Congress of the Society for Melanoma Research (SMR). Melanoma Institute Australia (MIA) has again sent an impressive number of delegates to present both oral presentations and posters with the latest in translational research.
Professor Georgina Long makes history as the first woman and first Australian to lead the Society for Melanoma Research
Professor Georgina Long makes history as the first woman and first Australian to lead the world’s most prestigious international melanoma research association.
Two publications co-edited by MIA Co-Medical Director Professor Richard Scolyer are now available to healthcare professionals. They aim to provide assistance in the care and management of patients with skin cancer, including melanoma.
Melanoma Institute Australia has introduced a new educational program to teach teenagers about the dangers of melanoma and the importance of sun safety.
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.